30th Oct 2009 12:30
Pfizer today announced that it has received the requisite consents to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary:
| Debt Security Description | CUSIP No. | Aggregate PrincipalAmount | ||||||||||||||||||||||
| 6.700% Notes due 2011 | 026609AM | $1,497,580,000 | ||||||||||||||||||||||
| 6.700% Notes due 2011 | 026609AJ | $2,420,000 | ||||||||||||||||||||||
| 5.250% Notes due 2013 | 983024AA | $1,500,000,000 | ||||||||||||||||||||||
| 5.500% Notes due 2014 | 983024AE | $1,750,000,000 | ||||||||||||||||||||||
| 5.500% Notes due 2016 | 983024AJ | $1,000,000,000 | ||||||||||||||||||||||
| 5.450% Notes due 2017 | 983024AM | $500,000,000 | ||||||||||||||||||||||
| 7.250% Notes due 2023 | 026609AC | $250,000,000 | ||||||||||||||||||||||
| 6.450% Notes due 2024 | 983024AF | $500,000,000 | ||||||||||||||||||||||
| 6.500% Notes due 2034 | 983024AG | $750,000,000 | ||||||||||||||||||||||
| 6.000% Notes due 2036 | 983024AL | $500,000,000 | ||||||||||||||||||||||
| 5.950% Notes due 2037 | 983024AN | $2,000,000,000 |
D.F. King, the Tabulation Agent, has advised that as of the expiration of the consent solicitation at 5:00 p.m., New York City time, on October 29, 2009, Pfizer had received the requisite consents in respect of at least a majority in aggregate principal amount of Securities outstanding as of the record date, 5:00 p.m. New York City Time, October 14, 2009. As a result, Pfizer and Wyeth will enter into a supplemental indenture to amend the indenture governing the Securities. In addition, Pfizer will (i) issue an unconditional and irrevocable guarantee of the prompt payment, when due, of any amounts owed in respect of the Securities and (ii) make a payment to each holder who validly delivered its consent prior to the expiration of the solicitation and did not revoke such consent of $1.50 for each $1,000 principal amount of Securities to which such consent relates.
The detailed terms and conditions of the consent solicitation are set forth in a Consent Solicitation/Prospectus Supplement dated October 16, 2009, which has been filed with the Securities and Exchange Commission.
Barclays Capital acted as Solicitation Agent for the consent solicitation, and D.F. King acted as the Information Agent and Tabulation Agent.
This announcement is for informational purposes only and is not an offer to purchase or sell, a solicitation of an offer to purchase or sell, or a solicitation of consents with respect to any securities.
| Pfizer |
| Media: |
| Joan Campion, 212-733-2798 |
| or |
| Investor: |
| Suzanne Harnett, 212-733-8009 |
Copyright Business Wire 2009
Related Shares:
PFZ.L